Blerp – Lifestyle
Author:
Ipsen Pharma
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
April 22, 2026
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
March 18, 2026
Ipsen appoints Michelle C. Werner as EVP, President of North America
March 12, 2026
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
March 9, 2026